Latest news with #IvanaMagovevi-Liebisch
Yahoo
22-05-2025
- Business
- Yahoo
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. 'We are incredibly proud of the legacy we have built at Vigil and today's announcement is a testament to the value of our TREM2 agonist pipeline,' said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. 'Sanofi's development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer's disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease.' Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See Insiders' Hot Stocks on TipRanks >> Read More on VIGL: Disclaimer & DisclosureReport an Issue Vigil Neuroscience Inc trading halted, news pending Vigil Neuroscience Advances Clinical Trials and Financial Stability Vigil Neuroscience reports Q1 EPS (49c) vs. (50c) last year Vigil Neuroscience sees cash runway into 2026 Vigil presents data on oral small molecule program including VG-3927 Sign in to access your portfolio
Business Insider
22-05-2025
- Business
- Business Insider
Vigil Neuroscience to be acquired by Sanofi for $8.00 per share
Vigil Neuroscience (VIGL) and Sanofi (SNY) announced that it has entered into a definitive merger agreement pursuant to which Sanofi will acquire Vigil for an upfront payment of $8.00 per share of common stock in cash. Vigil shareholders will also receive a non-tradeable contingent value right entitling the holder to potentially receive an additional $2.00 per share in cash payable following the first commercial sale of VG-3927 if achieved within a specific period. The total equity value of the transaction, including the potential CVR payment, represents approximately $600 million on a fully diluted basis. 'We are incredibly proud of the legacy we have built at Vigil and today's announcement is a testament to the value of our TREM2 agonist pipeline,' said Ivana Magovevi-Liebisch, Ph.D., J.D., President and Chief Executive Officer of Vigil. 'Sanofi's development capabilities, therapeutic expertise, global footprint, and financial strength provide the greatest opportunity to further the development of VG-3927 for the potential treatment of Alzheimer's disease and potentially bring this important and differentiated therapy to those struggling with the immense burden of this disease.' Confident Investing Starts Here:
